# Cardarine (GW-501516)

*Also known as: GW-501516, GW, Endurobol*

PPARδ agonist (mislabeled as SARM); improves endurance. Not a hormone.

## Overview

Cardarine (GW-501516, endurobol) is a synthetic PPAR-delta agonist, frequently mislabeled as a SARM despite having no androgen receptor activity and not being a hormone. It activates the peroxisome proliferator-activated receptor delta, driving changes in fatty acid oxidation, mitochondrial function, and skeletal muscle oxidative capacity that improve endurance capacity in animal models. The compound has a roughly 20-hour half-life, supporting once-daily oral dosing, though solid human pharmacokinetic data are limited. Early development was abandoned after long-term animal studies showed a cancer signal, and it remains an unapproved, WADA-prohibited substance with no accepted clinical use. Because it is sold mislabeled or contaminated and carries documented long-term safety concerns, harm reduction prioritizes understanding that the risk is oncologic and cardiovascular rather than hormonal, independent third-party testing, and informed consent about the abandoned development history.

## Pharmacokinetics

- **Model tier:** simple
- **Half-life:** 0.8 days (20 hours)
- **Bioavailability:** 100%

## Dosing

- **Default dose:** 10 mg
- **Typical range:** 5–20 mg
- **Units:** ng/mL

## Harm reduction

- **Aromatizes:** No
- **Hepatotoxicity:** mild
- **Interaction notes:** Technically a PPARδ agonist, not a SARM. Cancer signal in long-term animal studies.

## Detection time (anti-doping)

- **Window:** 30–40 days post-last-dose
- **Target metabolite:** GW1516 sulfone metabolites
- **Assay:** LC-MS/MS
- **Notes:** Sulfone metabolites are the recommended target analytes. WADA: <100 pg/mL reported as atypical.

## Source

- **Label:** DrugBank (GW-501516)
- **URL:** https://go.drugbank.com/drugs/DB05416
- **Notes:** No good half-life source.

---

**Canonical URL:** https://anabolicdex.com/compounds/cardarine
**Plot:** https://anabolicdex.com/plot?compound=cardarine